116.43
price up icon2.26%   2.57
after-market After Hours: 116.45 0.02 +0.02%
loading
Abbott Laboratories stock is traded at $116.43, with a volume of 4.96M. It is up +2.26% in the last 24 hours and up +7.10% over the past month. Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$113.86
Open:
$114.46
24h Volume:
4.96M
Relative Volume:
0.85
Market Cap:
$202.52B
Revenue:
$40.73B
Net Income/Loss:
$5.56B
P/E Ratio:
39.60
EPS:
2.94
Net Cash Flow:
$5.65B
1W Performance:
+2.79%
1M Performance:
+7.10%
6M Performance:
-3.75%
1Y Performance:
+15.59%
1-Day Range:
Value
$114.32
$116.73
1-Week Range:
Value
$112.52
$116.73
52-Week Range:
Value
$89.67
$121.64

Abbott Laboratories Stock (ABT) Company Profile

Name
Name
Abbott Laboratories
Name
Phone
(224) 667-6100
Name
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Name
Employee
114,000
Name
Twitter
@AbbottNews
Name
Next Earnings Date
2024-07-18
Name
Latest SEC Filings
Name
ABT's Discussions on Twitter

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

Date Action Analyst Rating Change
May-30-24 Initiated Goldman Buy
Jul-21-23 Upgrade Wolfe Research Underperform → Peer Perform
May-30-23 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-20-23 Reiterated Barclays Overweight
Apr-20-23 Reiterated Bernstein Outperform
Apr-20-23 Reiterated JP Morgan Overweight
Apr-20-23 Reiterated Raymond James Outperform
Apr-20-23 Reiterated UBS Buy
Apr-20-23 Reiterated Wolfe Research Underperform
Mar-29-23 Initiated UBS Buy
Oct-26-22 Initiated Mizuho Neutral
Oct-18-22 Initiated Barclays Overweight
Oct-12-22 Initiated Jefferies Hold
Jul-06-22 Initiated Wolfe Research Underperform
Mar-02-22 Resumed BofA Securities Buy
Jan-27-22 Reiterated Credit Suisse Outperform
Jan-27-22 Reiterated Morgan Stanley Overweight
Jan-27-22 Reiterated Raymond James Outperform
Jan-27-22 Reiterated UBS Buy
Dec-10-21 Initiated RBC Capital Mkts Outperform
Oct-27-21 Upgrade Atlantic Equities Neutral → Overweight
Oct-14-21 Initiated Redburn Neutral
May-25-21 Initiated Barclays Overweight
Apr-15-21 Initiated Atlantic Equities Neutral
Jan-28-21 Upgrade BTIG Research Neutral → Buy
Sep-11-20 Initiated Wolfe Research Outperform
Jun-01-20 Downgrade Goldman Neutral → Sell
Mar-05-20 Initiated Citigroup Buy
Feb-13-20 Initiated Goldman Neutral
Feb-06-20 Resumed BTIG Research Neutral
Jan-02-20 Downgrade Guggenheim Buy → Neutral
Jun-13-19 Reiterated BofA/Merrill Buy
Feb-07-19 Reiterated BofA/Merrill Buy
Jan-02-19 Downgrade Citigroup Neutral → Sell
Nov-30-18 Upgrade Goldman Neutral → Buy
Oct-16-18 Initiated Barclays Overweight
Jun-27-18 Initiated Bernstein Outperform
Jan-30-18 Reiterated Citigroup Neutral
Jan-25-18 Reiterated Stifel Buy
Jan-25-18 Upgrade William Blair Mkt Perform → Outperform
Jan-03-18 Initiated Evercore ISI Outperform
Jan-02-18 Upgrade JP Morgan Neutral → Overweight
Jan-02-18 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-19-17 Reiterated RBC Capital Mkts Outperform
Oct-19-17 Reiterated Stifel Buy
View All

Abbott Laboratories Stock (ABT) Latest News

pulisher
04:36 AM

Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch

04:36 AM
pulisher
12:05 PM

3 Things You Need to Know if You Buy AbbVie Stock Today - The Motley Fool

12:05 PM
pulisher
11:31 AM

Report: Abbott begins leadless pacemaker launch in UK - Mass Device

11:31 AM
pulisher
10:00 AM

$12.5 Bn Influenza Vaccine Market to 2032 by Vaccine Type, Technology, Age Group, Route of Administration, and Region - GlobeNewswire Inc.

10:00 AM
pulisher
06:15 AM

Hematology Market Huge Growth in Future Scope 2024-2031 | Abbott - openPR

06:15 AM
pulisher
05:15 AM

Nerve Repair and Regeneration Market 2024 Growing Opportunity and Competitive landscape – Abbott Laboratories, Axogen Corporation, Baxter, Boston Scientific Corporation – Cauverynews - Cauverynews

05:15 AM
pulisher
04:55 AM

mHealth and Home Monitoring Market 2024: 76.7 Million Patients Worldwide were Remotely Monitored in 2023, Reflecting Growing Market Acceptance - GlobeNewswire Inc.

04:55 AM
pulisher
03:25 AM

Peripheral Vascular Devices Market 2024 Leading Competitors – Angioscore Inc., Abbott Laboratories, Edward Lifesciences Corporation, Jude Medical – Cauverynews - Cauverynews

03:25 AM
pulisher
Sep 08, 2024

We Bought The Most Profitable Healthcare Stock Ever - Nanalyze

Sep 08, 2024
pulisher
Sep 06, 2024

Abbott Hit With False Ad Suit Over Toddler Nutrition Drink - Law360

Sep 06, 2024
pulisher
Sep 06, 2024

Abbott, Baxter and Medtronic among firms hit with recalls - BioWorld Online

Sep 06, 2024
pulisher
Sep 06, 2024

Abbott FreeStyle Libre 3 CGM Recall Designated Class I - MD+DI

Sep 06, 2024
pulisher
Sep 06, 2024

September 2025 Options Now Available For Abbott Laboratories (ABT) - Nasdaq

Sep 06, 2024
pulisher
Sep 06, 2024

FDA hits Abbott FreeStyle Libre 3 recall with Class I tag - Medical Device Network

Sep 06, 2024
pulisher
Sep 06, 2024

Abbott's Lingo CGM System Gains U.S. Availability: Stock to Gain? - Zacks Investment Research

Sep 06, 2024
pulisher
Sep 06, 2024

Abbott brings 'world's first' dual-chamber leadless pacemaker to the UK - Med-Tech Innovation

Sep 06, 2024
pulisher
Sep 06, 2024

Abbott will test whether its 'pacemaker' for the brain can treat depression - Crain's Chicago Business

Sep 06, 2024
pulisher
Sep 06, 2024

NEC Infant Formula Update - LawyersandSettlements.com

Sep 06, 2024
pulisher
Sep 06, 2024

In Vitro Diagnostics (IVD) Quality Controls Global Markets, 2029 with Abbott, bioMerieux, F. Hoffmann-La Roche Ltd., Siemens Healthineers, and Thermo Fisher Scientific Dominating - GlobeNewswire Inc.

Sep 06, 2024
pulisher
Sep 06, 2024

Bombay High Court restrains Abbott's ad, grants temporary relief to HUL: Report - Storyboard18

Sep 06, 2024
pulisher
Sep 05, 2024

Abbott's Blood Sugar Sensor for People Without Diabetes Now Available for Sale - CNET

Sep 05, 2024
pulisher
Sep 05, 2024

Abbott expands pump partnerships, launches Lingo CGM - BioWorld Online

Sep 05, 2024
pulisher
Sep 05, 2024

Abbott Laboratories stock outperforms competitors despite losses on the day - MarketWatch

Sep 05, 2024
pulisher
Sep 05, 2024

How Abbott Labs Is Leaning Into Obesity Treatment, And Taking On Dexcom - Investor's Business Daily

Sep 05, 2024
pulisher
Sep 05, 2024

HC relief to Hindustan Unilever in row over Abbott Laboratories health drink ad - The Morning Context

Sep 05, 2024
pulisher
Sep 05, 2024

Abbott Laboratories Recalls Some Sensors For Its Popular FreeStyle Libre 3 Glucose Monitoring System - Yahoo Finance

Sep 05, 2024
pulisher
Sep 05, 2024

Is It Worth Investing in Abbott Based on Wall Street's Bullish Views? - Benzinga

Sep 05, 2024
pulisher
Sep 05, 2024

Bombay HC grants temporary relief to HUL in case against Abbott Ads - The Economic Times

Sep 05, 2024
pulisher
Sep 05, 2024

Safety update: Sensor issue with Abbott CGMs ruled a Class I recall - Cardiovascular Business

Sep 05, 2024
pulisher
Sep 05, 2024

Abbott launches over-the-counter glucose monitor, Lingo - Seeking Alpha

Sep 05, 2024
pulisher
Sep 05, 2024

Abbott partners with maker of ‘bionic pancreas’ - MedTech Dive

Sep 05, 2024
pulisher
Sep 05, 2024

Abbott follows rival Dexcom with OTC glucose monitor launch in US By Reuters - Investing.com

Sep 05, 2024
pulisher
Sep 05, 2024

Abbott follows rival Dexcom with OTC glucose monitor launch in US - Yahoo! Voices

Sep 05, 2024
pulisher
Sep 05, 2024

Abbott follows rival Dexcom with OTC glucose monitor launch in US - Reuters

Sep 05, 2024
pulisher
Sep 05, 2024

Abbott Launches OTC Continuous Glucose Monitor - MD+DI

Sep 05, 2024
pulisher
Sep 05, 2024

Abbott just launched a $49 continuous glucose monitor — for people without diabetes - Quartz

Sep 05, 2024
pulisher
Sep 05, 2024

Abbott launches Lingo over-the-counter CGM biosensor in the U.S. - Mass Device

Sep 05, 2024
pulisher
Sep 05, 2024

Abbott launches over-the-counter continuous glucose monitor in the US - Blue Water Healthy Living

Sep 05, 2024
pulisher
Sep 05, 2024

Abbott launches over-the-counter continuous glucose monitor in the US - The Denver Gazette

Sep 05, 2024
pulisher
Sep 05, 2024

Abbott Follows Rival Dexcom With OTC Glucose Monitor Launch in US - U.S. News & World Report

Sep 05, 2024
pulisher
Sep 05, 2024

Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance

Sep 05, 2024
pulisher
Sep 05, 2024

Abbott launches its first over-the-counter continuous glucose monitor in the U.S. - CNBC

Sep 05, 2024
pulisher
Sep 05, 2024

Abbott's Lingo™ Continuous Glucose Monitor for Health and Wellness Now Available in the U.S. - PR Newswire

Sep 05, 2024
pulisher
Sep 05, 2024

Rx Medical Food Market Growth in Future Scope 2024-2031 | Abbott - openPR

Sep 05, 2024
pulisher
Sep 04, 2024

Abbott Laboratories VP sells shares worth over $3,100 - Investing.com

Sep 04, 2024
pulisher
Sep 04, 2024

Abbott Laboratories stock underperforms Wednesday when compared to competitors - MarketWatch

Sep 04, 2024
pulisher
Sep 04, 2024

Abbott & Beta Bionics Form Collaboration - MD+DI

Sep 04, 2024
pulisher
Sep 04, 2024

Abbott’s Mitraclip third trial: Triumph, TEERs and nuanced results - BioWorld Online

Sep 04, 2024
pulisher
Sep 04, 2024

Bioelectric Medicine Market Dazzling Worldwide | Major Giants Medtronic, Abbott, NeuroPace - Daily News Mirror

Sep 04, 2024
pulisher
Sep 04, 2024

Abbott to Begin Clinical Trial Evaluating Deep Brain Stimulation for Depression - MarketWatch

Sep 04, 2024
pulisher
Sep 04, 2024

Abbott initiates study of deep-brain stimulation for treatment-resistant depression - Mass Device

Sep 04, 2024

Abbott Laboratories Stock (ABT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Abbott Laboratories Stock (ABT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
MCCOY JOHN A. JR.
VICE PRESIDENT
Sep 04 '24
Sale
114.83
27
3,100
18,681
medical_devices SYK
$362.78
price up icon 1.08%
medical_devices BSX
$82.65
price up icon 1.29%
medical_devices MDT
$90.62
price up icon 0.81%
medical_devices EW
$65.71
price down icon 1.65%
$85.12
price up icon 0.04%
Cap:     |  Volume (24h):